Title : Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study.

Pub. Date : 2012 May

PMID : 22245891






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The present study evaluated the efficacy and safety of vandetanib, an oral inhibitor of both VEGFR and EGFR, in patients with unresectable advanced HCC. vandetanib kinase insert domain receptor Homo sapiens
2 Vandetanib induced a significant increase in circulating VEGF and decrease in circulating VEGFR levels. vandetanib kinase insert domain receptor Homo sapiens